Gilead’s Price Battle with Express Scripts
Why has Gilead resisted lowering its Hepatitis C drug prices with Express Scripts' National Preferred Formulary, a list of approved and covered drugs for millions of Americans?
Continue reading »Why has Gilead resisted lowering its Hepatitis C drug prices with Express Scripts' National Preferred Formulary, a list of approved and covered drugs for millions of Americans?
Continue reading »A surge of new Hepatitis C infections is the ultimate result of ordinary people trying to relieve chronic pain.
Continue reading »Driving up the rate of new Hepatitis C infections, intravenous drug use is gaining popularity with today’s younger generation.
Continue reading »The focus of a wide range of clinical studies, curcumin has repeatedly demonstrated liver benefits. While more research is called for, there remains no concrete evidence that this herb specifically changes the outcome of viral hepatitis. However, the information gathered thus far overwhelmingly supports adding curcumin to a liver health routine.
Continue reading »Particularly valuable to those with Hepatitis C, a new investigation sheds light on the common misconception that veggie burgers are a liver-friendly food.
Continue reading »The Taiwan-based biopharmaceutical company PharmaEssentia Corp. is testing P1101, its third-generation PEG-interferon-alpha drug candidate. Because it is a longer-lasting, purer interferon that is less costly to produce, P1101 could enhance the treatment options for Hepatitis C and B.
Continue reading »The 20-year patent on pegylated interferon is up, allowing an Indian pharmaceutical company to devise and offer an effective medication at a fraction of the cost of the current treatment. The long-time hope of HCV patients of an affordable Hepatitis C treatment may soon be realized.
Continue reading »You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window